412 related articles for article (PubMed ID: 27306074)
1. The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.
Khanna R; Chande N; Vermeire S; Sandborn WJ; Parker CE; Feagan BG
Inflamm Bowel Dis; 2016 Jul; 22(7):1737-43. PubMed ID: 27306074
[TBL] [Abstract][Full Text] [Related]
2. New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us?
Chande N; Marshall JK; Seow CH; Sandborn WJ; Parker CE; Nelson S; Feagan BG
Inflamm Bowel Dis; 2015 Dec; 21(12):2948-57. PubMed ID: 26540276
[TBL] [Abstract][Full Text] [Related]
3. Difficult-to-treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment.
Caron B; Habert A; Bonsack O; Camara H; Jeanbert E; Parigi TL; Netter P; Danese S; Peyrin-Biroulet L
United European Gastroenterol J; 2024 Jun; 12(5):605-613. PubMed ID: 38594841
[TBL] [Abstract][Full Text] [Related]
4. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
Barré A; Colombel JF; Ungaro R
Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
[TBL] [Abstract][Full Text] [Related]
5. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
[TBL] [Abstract][Full Text] [Related]
6. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
Hagan M; Cross RK
Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
[TBL] [Abstract][Full Text] [Related]
7. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
Biemans VBC; van der Woude CJ; Dijkstra G; van der Meulen-de Jong AE; Löwenberg M; de Boer NK; Oldenburg B; Srivastava N; Jansen JM; Bodelier AGL; West RL; de Vries AC; Haans JJL; de Jong D; Hoentjen F; Pierik MJ;
Aliment Pharmacol Ther; 2020 Jul; 52(1):123-134. PubMed ID: 32441396
[TBL] [Abstract][Full Text] [Related]
8. Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center.
Dayan JR; Dolinger M; Benkov K; Dunkin D; Jossen J; Lai J; Phan BL; Pittman N; Dubinsky MC
J Pediatr Gastroenterol Nutr; 2019 Jul; 69(1):61-67. PubMed ID: 31058718
[TBL] [Abstract][Full Text] [Related]
9. [Emerging Therapies: What Are Promising in the Near Future?].
Seo GS; Lee SH
Korean J Gastroenterol; 2018 Feb; 71(2):81-88. PubMed ID: 29471605
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
11. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients.
Kawalec P; Moćko P
J Comp Eff Res; 2018 Feb; 7(2):101-111. PubMed ID: 29115855
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
Lam MC; Bressler B
Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
[TBL] [Abstract][Full Text] [Related]
13. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)
Ylisaukko-Oja T; Aaltonen J; Nuutinen H; Blomster T; Jussila A; Pajala M; Salminen K; Moilanen V; Hakala K; Kellokumpu M; Toljamo K; Rautiainen H; Kuisma J; Peräaho M; Molander P; Silvennoinen J; Liukkonen V; Henricson H; Tillonen J; Esterinen M; Nielsen C; Hirsi E; Lääne M; Suhonen UM; Vihriälä I; Mäkelä P; Puhto M; Punkkinen J; Sulonen H; Herrala S; Jokelainen J; Tamminen K; Sipponen T
Scand J Gastroenterol; 2018 Feb; 53(2):158-167. PubMed ID: 29258369
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
Domènech E; Gisbert JP
Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
[TBL] [Abstract][Full Text] [Related]
15. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.
Schneider AM; Weghuber D; Hetzer B; Entenmann A; Müller T; Zimmermann G; Schütz S; Huber WD; Pichler J
BMC Gastroenterol; 2018 Sep; 18(1):140. PubMed ID: 30219028
[TBL] [Abstract][Full Text] [Related]
16. The role of biologics in the treatment of patients with inflammatory bowel disease.
Selinger CP; Carbery I; Al-Asiry J
Br J Hosp Med (Lond); 2018 Dec; 79(12):686-693. PubMed ID: 30526103
[TBL] [Abstract][Full Text] [Related]
17. Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab.
Hinojosa Del Val J; Barreiro-de Acosta M
Gastroenterol Hepatol; 2019 Dec; 42(10):650-656. PubMed ID: 31635855
[TBL] [Abstract][Full Text] [Related]
18. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
[TBL] [Abstract][Full Text] [Related]
19. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.
Cohen RD; Bhayat F; Blake A; Travis S
J Crohns Colitis; 2020 Feb; 14(2):192-204. PubMed ID: 31504340
[TBL] [Abstract][Full Text] [Related]
20. Ustekinumab for the treatment of Crohn's disease.
Hansen T; Targownik LE
Expert Rev Gastroenterol Hepatol; 2016 Sep; 10(9):989-94. PubMed ID: 27450626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
